Prospective Grant of Exclusive License: Anti-Mesothelin Antibodies Useful for Immunological Assays, 34027 [E7-11828]

Download as PDF rwilkins on PROD1PC63 with NOTICES Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices Contact Person: Jay Joshi, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5184, MSC 7846, Bethesda, MD 20892, (301) 435–1184, joshij@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, Brain Disorders and Clinical NeuroscienceMembers. Date: July 19, 2007. Time: 2 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Jay Joshi, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5184, MSC 7846, Bethesda, MD 20892, (301) 435–1184, joshij@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, Xenopus Genetics and Genomics. Date: July 23–24, 2007. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: Barbara J. Thomas, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2218, MSC 7890, (301) 435–0603, bthomas@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, Small Business: Arthritis, Connective Tissue and Skin Sciences. Date: July 23, 2007. Time: 8 a.m. to 12 p.m. Agenda: To review and evaluate grant applications. Place: The Watergate Hotel, 2650 Virginia Avenue, NW., Washington, DC 20037. Contact Person: Harold M. Davidson, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4222, MSC 7814, Bethesda, MD 20892, (301) 435– 1776, davidsoh@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, Stem Cells, Neuron Migration and Guidance. Date: July 23, 2007. Time: 1 p.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Carol Hamelink, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5040H, MSC 7850, Bethesda, MD 20892, (301) 451– 1328, hamelinc@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, Small Business: Digestive Sciences and Bioengineering. VerDate Aug<31>2005 18:25 Jun 19, 2007 Jkt 211001 Date: July 23, 2007. Time: 1 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Bonnie L. Burgess-Beusse, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2191C, MSC 7818, Bethesda, MD 20892, (301) 435– 1783, beusseb@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.847–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: June 12, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–3014 Filed 6–19–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Anti-Mesothelin Antibodies Useful for Immunological Assays National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent Application No. 60/681,104, filed May 12, 2005, entitled ‘‘Anti-Mesothelin Antibodies Useful For Immunological Assays’’ [E– 015–2005/0–US–01] and PCT Application No. PCT/US2006/018502, filed May 11, 2006, entitled ‘‘AntiMesothelin Antibodies Useful For Immunological Assays’’ [E–015–2005/0– PCT–02] to Cambridge Antibody Technology, Ltd., which has offices in Cambridge, United Kingdom. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to the use of the SSIP immunoconjugate and variants thereof for the treatment of mesothelin expressing cancers. DATES: Only written comments and/or applications for a license which are received by the NIH Office of PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 34027 Technology Transfer on or before August 20, 2007 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Jesse S. Kindra, J.D., M.S., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 5559; Facsimile: (301) 402–0220; E-mail: kindraj@mail.nih.gov. SUPPLEMENTARY INFORMATION: This technology relates to anti-mesothelin antibodies with a particularly high affinity for mesothelin and the ability to be used in immunological assays for detecting the presence of mesothelin in biological samples. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: June 11, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer,Office of Technology Transfer, National Institutes of Health. [FR Doc. E7–11828 Filed 6–19–07; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY The Critical Infrastructure Partnership Advisory Council (CIPAC) Directorate for National Protection and Programs, DHS. ACTION: Committee management; update on CIPAC committee membership. AGENCY: E:\FR\FM\20JNN1.SGM 20JNN1

Agencies

[Federal Register Volume 72, Number 118 (Wednesday, June 20, 2007)]
[Notices]
[Page 34027]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-11828]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Anti-Mesothelin 
Antibodies Useful for Immunological Assays

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive patent license to practice the inventions embodied in U.S. 
Patent Application No. 60/681,104, filed May 12, 2005, entitled ``Anti-
Mesothelin Antibodies Useful For Immunological Assays'' [E-015-2005/0-
US-01] and PCT Application No. PCT/US2006/018502, filed May 11, 2006, 
entitled ``Anti-Mesothelin Antibodies Useful For Immunological Assays'' 
[E-015-2005/0-PCT-02] to Cambridge Antibody Technology, Ltd., which has 
offices in Cambridge, United Kingdom. The patent rights in these 
inventions have been assigned to the United States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to the use of the SSIP immunoconjugate 
and variants thereof for the treatment of mesothelin expressing 
cancers.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
August 20, 2007 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Jesse S. Kindra, J.D., M.S., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; Telephone: (301) 435-5559; Facsimile: (301) 402-0220; E-
mail: kindraj@mail.nih.gov.

SUPPLEMENTARY INFORMATION: This technology relates to anti-mesothelin 
antibodies with a particularly high affinity for mesothelin and the 
ability to be used in immunological assays for detecting the presence 
of mesothelin in biological samples. The anti-mesothelin antibodies are 
well-suited for the diagnosis and treatment of cancers of the ovary, 
stomach, squamous cells, mesotheliomas and other malignant cells 
expressing mesothelin.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 
404.7. The prospective exclusive license may be granted unless within 
sixty (60) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: June 11, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer,Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E7-11828 Filed 6-19-07; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.